Rosuvastatin
Brand names: Crestor · Active ingredient: Rosuvastatin
In short: Rosuvastatin tablets are indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for these events. As an adjunct to diet and exercise to reduce low-de
What is Rosuvastatin used for?
Rosuvastatin tablets are indicated:
To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for these events.
As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C):
in adults with hypercholesterolemia.
and slow the progression of atherosclerosis in adults.
in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).
As an adjunct to diet for the treatment of adults with:
Primary dysbetalipoproteinemia.
Hypertriglyceridemia.
Rosuvastatin dosage
Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food. Swallow the tablets whole.
Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets and adjust the dosage if necessary.
If a dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose.
When taking rosuvastatin tablets with an aluminum and magnesium hydroxide combination antacid, administer rosuvastatin tablets at least 2 hours before the antacid
.
The dosage range for rosuvastatin tablets is 5 mg to 40 mg orally once daily.
The recommended dosage of rosuvastatin tablets depends on a patient’s indication for usage, LDL-C, and individual risk for CV events.
Dosage in Pediatric Patients 8 Years of Age and Older with HeFH
The recommended dosage range is 5 mg to 10 mg orally once daily in patients aged 8 years to less than 10 years and 5 mg to 20 mg orally once daily in patients aged 10 years and older.
Dosage in Pediatric Patients 7 Years of Age and Older with HoFH
The recommended dosage is 20 mg orally once daily.
Initiate rosuvastatin tablets at 5 mg orally once daily due to increased rosuvastatin plasma concentrations. Consider the risks and benefits of rosuvastatin tablets when treating Asian patients not adequately controlled at dosages up to 20 mg orally once daily
[see
Warnings and Precautions (5.1),
Use in Specific Populations (8.8), and
Clinical Pharmacology (12.3)].
In patients with severe renal impairment (CL
crless than 30 mL/min/1.73 m
2) not on hemodialysis, the recommended starting dosage is 5 mg orally once daily and should not exceed 10 mg orally once daily
.
There are no dosage adjustment recommendations for patients with mild and moderate renal impairment.
Table 1 displays dosage modifications for rosuvastatin tablets due to drug interactions
.
Concomitantly Used Drug | Rosuvastatin tablets Dosage Modifications
Sofosbuvir/velpatasvir/voxilaprevir or Ledipasvir/sofosbuvir | Avoid concomitant use.
Gemfibrozil | Avoid concomitant use. If use is unavoidable, initiate at 5 mg once daily and do not exceed 10 mg once daily.
Tafamidis | Avoid concomitant use. If use is unavoidable, initiate at 5 mg once daily and do not exceed 20 mg once daily.
Belumosudil | Do not exceed 5 mg once daily.
Cyclosporine | Do not exceed 5 mg once daily.
Darolutamide | Do not exceed 5 mg once daily.
Vadadustat | Do not exceed 5 mg once daily.
Additional Antiviral Medications
Simeprevir
Dasabuvir/ombitasvir/paritaprevir/ritonavir
Elbasvir/Grazoprevir
Sofosbuvir/Velpatasvir
Glecaprevir/Pibrentasvir
Atazanavir/Ritonavir
Lopinavir/Ritonavir | Initiate at 5 mg once daily. Do not exceed 10 mg once daily.
Capmatinib | Do not exceed 10 mg once daily.
Enasidenib | Do not exceed 10 mg once daily. …
How to take Rosuvastatin — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (
Patient Information).
Myopathy and Rhabdomyolysis
Advise patients that rosuvastatin tablets may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over-the-counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever
.
Hepatic Dysfunction
Inform patients that rosuvastatin tablets may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice
.
Increases in HbA1c and Fasting Serum Glucose Levels
Inform patients that increases in HbA1c and fasting serum glucose levels may occur with rosuvastatin tablets. Encourage patients to optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices
.
Pregnancy
Advise pregnant patients and patients who can become pregnant of the potential risk to a fetus. …
Warnings & precautions
Do not take this medicine if: Rosuvastatin tablets are contraindicated in patients with:
Acute liver failure or decompensated cirrhosis
.
Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin tablets
.
Rosuvastatin may cause myopathy [muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK)] and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis with statins, including rosuvastatin.
Risk Factors for Myopathy
Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher rosuvastatin dosage. Asian patients on rosuvastatin may be at higher risk for myopathy
. The myopathy risk is greater in patients taking rosuvastatin 40 mg daily compared with lower rosuvastatin dosages.
Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis
Rosuvastatin dosage modifications are recommended for patients taking certain medications; concomitant use with certain other medications should be avoided .
Discontinue rosuvastatin if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if rosuvastatin is discontinued. Temporarily discontinue rosuvastatin in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the rosuvastatin dosage. …
Rosuvastatin side effects
The following important adverse reactions are described below and elsewhere in the labeling:
Myopathy and Rhabdomyolysis
Immune-Mediated Necrotizing Myopathy
Hepatic Dysfunction
Proteinuria and Hematuria
Increases in HbA1c and Fasting Serum Glucose Levels
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adverse reactions reported in ≥2% of patients in placebo-controlled clinical studies and at a rate greater than placebo are shown in Table 2. These studies had a treatment duration of up to 12 weeks.
Adverse Reactions | Placebo
N=382% | Rosuvastatin
5 mg
N=291% | Rosuvastatin
10 mg
N=283% | Rosuvastatin
20 mg
N=64% | Rosuvastatin
40 mg
N=106% | Total Rosuvastatin
5 mg to 40 mg
N=744%
Headache | 5.0 | 5.5 | 4.9 | 3.1 | 8.5 | 5.5
Nausea | 3.1 | 3.8 | 3.5 | 6.3 | 0 | 3.4
Myalgia | 1.3 | 3.1 | 2.1 | 6.3 | 1.9 | 2.8
Asthenia | 2.6 | 2.4 | 3.2 | 4.7 | 0.9 | 2.7
Constipation | 2.4 | 2.1 | 2.1 | 4.7 | 2.8 | 2.4
Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity (including rash, pruritus, urticaria, and angioedema) and pancreatitis. …
Drug interactions
Rosuvastatin is a substrate of CYP2C9 and transporters (such as OATP1B1, BCRP). Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. Table 5 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with rosuvastatin and instructions for preventing or managing them
.
Sofosbuvir/velpatasvir/voxilaprevir or Ledipasvir/sofosbuvir
Prevention or Management: | Avoid concomitant use with rosuvastatin.
Mechanism and Clinical Effect(s): | Rosuvastatin plasma levels were significantly increased with concomitant administration of many anti-viral drugs, which increases the risk of myopathy and rhabdomyolysis.
Gemfibrozil
Prevention or Management: | Avoid concomitant use of gemfibrozil with rosuvastatin. If use is unavoidable, initiate rosuvastatin at 5 mg once daily and do not exceed a dosage of rosuvastatin 10 mg once daily.
Mechanism and Clinical Effect(s): | Gemfibrozil significantly increased rosuvastatin exposure and gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use.
Tafamidis
Prevention or Management: | Avoid concomitant use of tafamidis with rosuvastatin. …
About this medicine
Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor.
The chemical name for rosuvastatin calcium, USP is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2Â [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula:
The empirical formula for rosuvastatin calcium is (C
22H
27FN
3O
6S)
2Ca and the molecular weight is 1001.14. Rosuvastatin calcium, USP is a white to almost white amorphous powder that is sparingly soluble in water and methanol, and slightly soluble in ethanol. Rosuvastatin calcium is a hydrophilic compound with a partition coefficient (octanol/water) of 1.4 at pH of 7.0. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ee4933c5-0d97-494d-ac0f-2083e0100836. Read the full official label on DailyMed.
Related medicines
Atorvastatin Amlodipine Lisinopril Losartan Metoprolol Simvastatin Spironolactone Pravastatin